Patent Grant
11553712
The present disclosure relates to uses, methods and compositions for the inactivation of pathogens in biological compositions.
Use of biological compositions is important for developing and producing therapeutics (e.g., the production of recombinant proteins). Biological compositions, such as blood compositions, save many lives by blood transfusion for instance, for patients having a blood disease, a haemorrhage, or undergoing a surgical procedure. However, the presence of pathogens in biological compositions presents a significant health risk.
Methods to inactivate pathogens in biological compositions have been developed. Classical pathogen inactivation methods include approaches based on heat treatment, solvent and/or detergent treatment, gamma irradiation, UV treatment, and leukodepletion. However, the efficiency and effectiveness of said methods varies because of the different sensitivities of pathogens and incompatibility of some methods with specific biological compositions.
There is a need for new pathogen inactivation methods and agents.
The present disclosure relates to uses, methods, agents and compositions for the inactivation of pathogens in biological compositions.
In one aspect the disclosure relates to the use of a glycol as a pathogen inactivating agent. In some embodiments the glycol is propylene glycol.
In one aspect the disclosure relates to methods for inactivating a pathogen in a biological composition, said method comprising contacting said biological composition with a glycol. In some embodiments for inactivating a pathogen in a biological composition, the glycol is propylene glycol. In some embodiments for inactivating a pathogen in a biological composition, said biological composition is a blood composition or a milk composition. In some embodiments for inactivating a pathogen in a biological composition, said pathogen is selected from the group consisting of viruses, bacteria, fungi, protozoa, parasites, and prions. In some embodiments said virus is selected from the group consisting of X-MuLV, PRV, BVDV and TGEV virus. In some embodiments for inactivating a pathogen in a biological composition, said method results in a pathogen elimination equal or greater than 4 Log10TCID (Tissue Culture Infective Dose) according to the methods of Kärber and/or Spearman-Kärber. In some embodiments for inactivating a pathogen in a biological composition, the concentration of glycol after the contacting step is between 40 and 50% (w/w) of the biological composition. In some embodiments for inactivating a pathogen in a biological composition, the concentration of glycol after the contacting step is between 40 and 50% (v/v) of the biological composition. In some embodiments for inactivating a pathogen in a biological composition, said method is performed at a temperature between 15 and 25° C. In some embodiments for inactivating a pathogen in a biological composition, said method is performed at a pH between 7.0 and 8.0.
In one aspect the disclosure relates to a biological composition comprising a glycol, wherein said biological composition is obtained by any of the methods described herein In some embodiments said glycol is at a concentration between 40 and 50%. In some embodiments said glycol is propylene glycol. In some embodiments the biological composition is a milk composition or a blood composition.
The drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. The figures are illustrative only and are not required for enablement of the disclosure.
In one aspect the disclosure relates to the use of a glycol as a pathogen inactivating agent. In one aspect the disclosure relates to methods for inactivating pathogens in a biological composition, said method comprising contacting said biological composition with a glycol. In one aspect the disclosure relates to a biological composition comprising glycol. In some embodiments said biological composition comprising glycol is obtained by any of the methods described herein.
In some embodiments of the uses, methods and compositions described herein, the glycol is vicinal glycol. In some embodiments the vicinal glycol is propylene glycol or ethylene glycol.
The term “glycol” (or “diol”) refers to a chemical compound containing two hydroxyl groups (—OH). The term “vicinal glycol” refers to a glycol with two hydroxyl groups attached to adjacent atoms (e.g., in vicinal position).
In some embodiments the glycol used in the methods and compositions described herein is a vicinal glycol comprising between two and six carbons and having a chemical formula R1R2—(C—OH)2—R3R4, wherein R1, R2, R3 and R4 may be identical or different and are each either a hydrogen atom or an alkyl group, wherein the combination of R1, R2, R3 and R4 contains at most two carbon atoms. Examples of vicinal glycols are propylene glycol, ethylene glycol, 1,2-butanediol and 1,2-pentanediol.
In some embodiments of the uses, methods and compositions described herein, the glycol is propylene glycol or ethylene glycol.
The term “propylene glycol”, also called “1,2-dihydroxypropane” or “methyl glycol”, refers to propane-1,2-diol and has the structural formula (I) represented below.
The term “ethylene glycol”, also called “1,2-dihydroxyethane”, refers to ethane-1,2-diol and has the structural formula (II) represented below.
In some embodiments of the uses, methods and compositions described herein, the glycol is a geminal glycol. Geminal glycols have two hydroxyl groups attached to the same carbon atom and include 1,2-methane diol, 1,2-ethane diol and 1,2-propanediol. In some embodiments of the uses, methods and compositions described herein, the glycol is a diol wherein the hydroxyl groups are not on the same or adjacent carbon atoms. Examples of such glycols are 1,3-butanediols, 1,4-pentanediols, and 1,3-benzenediol.
In one aspect the disclosure relates to pathogen inactivating agents, compositions that comprise such agents and uses thereof.
The term “pathogen” refers to any biological agent (e.g., any nucleic acid containing agent or proteinaceous infectious particle such as a prion) that can cause disease in a mammal, such as a human. The term pathogen includes unicellular and multicellular microorganisms, with DNA or RNA as genetic material, in single-stranded or double-stranded form. The term particularly includes viruses, bacteria, fungi, protozoa and prions. Examples of bacteria include, but are not limited to, Streptococcus, Escherichia and Bacillus species; examples of viruses include, but are not limited to, the Human Immunodeficiency Virus (HIV) and other retroviruses, the herpesviruses, the paramyxoviruses, the poxviruses, the togaviruses, the cytomegaloviruses and the hepatitis viruses (HAV, HBV, HCV); examples of parasites include, but are not limited to, malaria parasites (Plasmodium species) and trypanosomal parasites.
In some embodiments of the disclosure, said pathogen to be inactivated is selected from the group consisting, of viruses, bacteria, fungi, protozoa, parasites and prions.
In some embodiments said pathogen is a virus.
In some embodiments said virus is an enveloped virus or a non-enveloped virus.
Enveloped viruses are viruses that have a host-cell-like “envelope” and include for example, but are not limited to, mammalian or avian Leukemia viruses, Herpes viruses, Pox viruses, Hepadnaviruses, Flaviviruses, Togaviruses, Coronaviruses, Hepatitis viruses, Retroviruses, Orthomyxoviruses, Paramyxoviruses, Rhadoviruses, Bunyaviruses, Filoviruses and Reoviruses. Non-enveloped viruses, also called naked viruses, are well known in the art and include, but are not limited to, adenoviruses, norovirus, rotavirus and human pappillomavirus.
In a some embodiments the virus is X-MuLV, PRV, TGEV or BVDV. The term “X-MuLV” for “Xenotropic murine leukemia virus-related virus” refers to a gammaretrovirus. The term “PRV” refers to a pseudorabies virus. The term “TGEV” for “Transmissible Gastroenteritis Coronavirus” refers to a species of animal virus belonging to the family of Coronaviruses. The term “BVDV” for “Bovine viral diarrhea virus” is a pestivirus from the family of flaviviruses.
In one aspect the disclosure relates to methods for inactivating pathogens in a biological composition, said method comprising contacting said biological composition with a glycol.
As used herein, the term “contacting” refers to a process of bringing into contact at least two distinct compositions or components such that they can interact.
The term “biological composition” refers to a composition (or a material) originating from a biological organism, including mammals. Examples of biological compositions include, but are not limited to, blood compositions, milk (such as milk from transgenic mammals), clinical samples such as urine, sweat, sputum, feces and spinal fluid, cellular and tissue extracts, cell culture medium, etc. As used herein, biological compositions also include synthetic compositions that can function as biological compositions, such as blood substitutes, and compositions that have undergone one or more purification or separation steps.
According to the disclosure a blood composition includes, but is not limited to, whole blood and blood products. The term “blood product” refers to one or more components that may be separated from whole blood, and encompasses cellular blood component (such as erythrocytes or red blood cells, platelets, leukocytes and concentrates thereof), blood proteins (such as blood clotting factors, enzymes, albumin, plasminogen, immunoglobulins) and blood fluid components (such as plasma, fractions of blood plasma and serum). In some embodiments the blood composition is leukodepleted (e.g., depleted in leukocytes).
In some embodiments the blood composition to be treated is selected from the group consisting of whole blood, erythrocytes concentrates, platelets concentrates, plasma and fractions of blood plasma.
In some embodiments the biological composition is a milk composition. In some embodiments the milk composition to be treated is derived from milk of a transgenic animal that produces a protein of interest secreted in said milk.
In some embodiments the method is performed on an eluate in a process of purification, such as by affinity chromatography, of a biological composition, such as a milk composition.
The terms “pathogen inactivation” or “inactivating pathogens”, as used herein, refer to the suppression or inhibition of the replication (or reproduction) of said pathogens, and/or their destruction or elimination. Typically, a pathogen inactivating agent severely or at least substantially hampers the ability of the pathogen to replicate or reproduce under appropriate conditions.
Methods for determining if a particular method results in the suppression or inhibition of replication of pathogens are well known in the art. Typically such methods include the steps of determining the number of (active) pathogens prior to treatment with a pathogen inactivating agent and determining the number of (active) pathogens after treatment. The particular method for determining the number of active pathogens will depend on the nature of the pathogen and includes colony forming assays (for determining the number of active bacteria) and infective assays (for determining the number of “active” viruses). One measure of the number of active viruses is the Tissues Culture Effective Dose (TCID), which can be determined for instance by the Kärber and/or Spearman-Kärber methods. (See e.g., Karber, G. (1931). Arch. J. Exper. Path. u. pharmakol., 162, 480; Spearman (1908). Brit. J. Psychol., 2:227-242)
In some embodiments the methods of the disclosure result in pathogen elimination higher or equal to 4 Log10TCID. The pathogen elimination may be calculated according to the methods of Kärber and/or Spearman-Kärber as explained in the examples.
In some embodiments the biological composition, after the contacting step, will contain an amount of glycol sufficient to inactivate, eliminate or lower the amount of pathogen, for example, below a desired level. In some embodiments the glycol concentration in the biological composition after the contacting step is between 10% and 75% (w/w), between 15% and 70% (w/w), between 20% and 65% (w/w), between 25% and 60% (w/w), between 30% and 60% (w/w), between 35% and 55% (w/w), or between 40% and 50% (w/w) of the composition. In some embodiments the glycol concentration in the biological composition after the contacting step is between 10% and 75% (v/v), between 15% and 70% (v/v), between 20% and 65% (v/v), between 25% and 60% (v/v), between 30% and 60% (v/v), between 35% and 55% (v/v), or between 40% and 50% (v/v) of the composition.
While not required, generally, it is expected that the pathogen inactivation increases with the length of exposure of the biological composition comprising the pathogen to the glycol. In some embodiments the biological composition is contacted with the glycol for a duration that permits pathogen elimination greater than or equal to 4 Log TCID (Tissue Culture Infective Dose)
In some embodiments the biological composition is contacted with the glycol for at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, at least 70 minutes, at least 80 minutes, at least 90 minutes, at least 1200 minutes, at least 150 minutes, at least 180 minutes, at least 210 minutes, at least 240 minutes, at least 300 minutes, at least 360 minutes, at least 2500 minutes, at least 1000 minutes, or more. In some embodiments the biological composition is contacted with the glycol for a duration between 15 and 360 minutes, between 60 and 240 minutes, or between 90 and 180 minutes. In some embodiments the glycol is removed from the biological composition after a specific amount of pathogen inactivation has been achieved. In some embodiments the glycol remains present in the biological composition after the inactivation of the pathogen.
In some embodiments of the methods described herein are performed at a temperature between 10 and 30° C., between 12 and 28° C., or between 15 and 25° C.
In some embodiments the methods described herein are performed at a pH between 4 and 11, between 5 and 10, between 6 and 9, between 6.5 and 8.5, or between 7 and 8. In some embodiments the methods described herein are performed at a pH of around 7.5. In some embodiments the methods described herein are performed at a pH of 7.5. A person of ordinary skill in the art can rely on the literature to determine which pH range is acceptable for a particular biological composition.
In some embodiments the methods comprise a further step of viral elimination such as nanofiltration.
In some embodiments the methods are performed during an elution phase in a process of purification, such as affinity chromatography, of a biological composition. In some embodiments the glycol is added to an affinity elution buffer. In some embodiments an affinity elution buffer comprises 50 mM tris, 45% (w/w/) propylene glycol and 1.5M NaCl and has a pH of 7.5. In some embodiments an affinity elution buffer comprises 50 mM tris, 45% (v/v/) propylene glycol and 1.5M NaCl and has a pH of 7.5.
In some embodiments the methods described herein do not comprise a step of contacting the biological composition with cruciferous oil or with arginine in a significant amount.
A significant amount of arginine, as used herein, corresponds to an arginine concentration of at least 0.2M, at least 0.01M, or at least 0.001M, after the contacting step.
A significant amount of cruciferous oil, as used herein, corresponds to a concentration of at least 0.1% of said cruciferous oil, at least 0.01%, or at least 0:001%, after the contacting step.
In one aspect the disclosure relates to a biological composition comprising glycol for inactivating pathogens, wherein said biological composition is obtained by contacting a biological composition with a glycol, such as by any of the methods described herein.
In some embodiments said glycol is propylene glycol or ethylene glycol.
In some embodiments the glycol concentration in the biological composition is between 10% and 75% (w/w), between 15% and 70% (w/w), between 20% and 65% (w/w), between 25% and 60% (w/w), between 30% and 60% (w/w), between 35% and 55% (w/w), or between 40% and 50% (w/w) of the composition. In some embodiments the glycol concentration in the biological composition is between 10% and 75% (v/v), between 15% and 70% (v/v), between 20% and 65% (v/v), between 25% and 60% (v/v), between 30% and 60% (v/v), between 35% and 55% (v/v), or between 40% and 50% (v/v) of the composition.
In some embodiments the biological composition also comprises a detergent such as TWEEN 20 or TWEEN 80. In some embodiments the biological composition also comprises a solvent such as TNBP (Tri-N-butyl Phosphate). In some embodiments the biological composition comprised a detergent prior to contacting with glycol. In some embodiments the biological composition is contacted with a detergent prior to contacting with glycol. In some embodiments the biological composition is contacted with a detergent simultaneously with contacting with glycol. In some embodiments the biological composition is contacted with a detergent after contacting with glycol.
In some embodiments the biological composition does not comprise arginine in a significant amount.
In some embodiments the biological composition does not comprise cruciferous oil in a significant amount.
In some embodiments the biological composition does not comprise either arginine or cruciferous oil in a significant amount.
The following examples describe some embodiments of making and practicing the methods and compositions of the disclosure. However, it should be understood that the examples are for illustrative purposes only and are not meant to limit the scope of the disclosure. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.
Material and Methods
The inactivation of two enveloped viruses (TGEV and BVDV) by propylene glycol (PG) present at 45% (v/v) in an affinity chromatography eluate was evaluated. The eluate was generated during the production of a transgenic protein of interest (in a milk composition derived from a transgenic animal producing said protein, which is secreted in its milk).
Cytotoxicity, Viral Interference and Quenching.
The cytotoxicity, viral interference and quenching parameters of the starting material (the eluate) were determined prior to the incubation assay in presence of PG. The assays to determine the cytotoxicity, viral interference and quenching were done on the eluate sample of an affinity chromatography.
Cytotoxicity.
The cytotoxicity parameters of the starting material were evaluated using the conditions in Table I:
The non cytotoxic concentration of the sample matrix is defined as the first dilution of the sample matrix that does not involve any destruction of the cell coat of cells incubated into the matrix.
The cytotoxicity parameters obtained at Day +3 in this assay were used to determine the viral interference conditions and were confirmed at Day +6.
Viral Interference Control and Sample Quenching.
The viral interference and the sample quenching parameters were determined simultaneously.
The viral interference parameters of a sample for the titration system were evaluated. The assay consists of a dilution titration of the viruses BVDV and TGEC in a sample matrix (first dilution point: non-cytotoxic matrix, as determined above) compared with a titration in a culture medium. Before determining the appropriate dilutions of the viruses, a 30 minutes incubation period at 4° C. was performed in order to mimic the assay environment, as the actual assay has latency times of 15-30 minutes prior to the titration of fractions at T0, T5 and T15.
The potential interference of the matrix with both titration systems (ST and MDBK cells) was evaluated according to the operating conditions shown in Table II.
The viral interference/quenching by the matrix was determined to be significant if a difference >1.0 log10 TCID50/mL was observed between the titration in sample matrix (the eluate) and the titration in culture medium.
Process
Operating Conditions.
The kinetics of the inactivation of the enveloped viruses (TGEV and BVDV) by the propylene glycol (PG) was evaluated by contacting the viruses for six hours at 20° C. (±5° C.) with the eluate of the affinity chromatography containing 45% (v/v) PG as obtained during the purification process of the transgenic protein. The virus was added to the sample at a concentration of 5% (v/v). For each virus, the assay was performed in duplicate.
Material.
The starting material was an affinity chromatography eluate. The starting material was spiked with virus at 5% (v/v).
The conditions of the viral suspensions of TGEV and BVDV used in this assay are described in Table III (TEGV) and Table IV (BVDV).
Respective cell Culture media (for ST and MDBK cells) were used during the neutralization step. This neutralization was performed at concentrations determined in the assays on the cytotoxicity, the viral interference and the matrix quenching.
Assay.
A beaker was placed in a heating device at 20° C.±5° C. The beaker was placed on a magnetic stirrer and maintained at 20° C.±5° C. before treatment.
For each assay, an aliquot of starting material (20 mL) was thawed in a water bath at 20° C.±5° C. After thawing, the temperature was checked.
Each aliquot (≥1 mL) of viral suspension was thawed at ambient temperature. An aliquot of about 0.1 mL was stored at a temperature lower than −65° C. The viral suspension was used to create a sample of the starting material containing 5% of virus.
The treatment consist of spiking 1 mL (5%) of viral suspension in 19 mL of matrix containing 45% of PG (obtained from the eluate of the affinity chromatography).
After a rapid homogenization and a check of the temperature of the mixture, a sample aliquot (1 mL) was taken and quenched with culture medium (ST cell culture medium or MDBK cell culture medium, depending on the cell line used). The added volume of cell culture medium depended on the data obtained in the cytotoxicity, interference and viral quenching study. This sample constituted the “T0”.
The virus-spiked material (containing PG at 45% (v/v) was incubated for six hours at 20° C.±5° C. in the same manner as for the “T0” sample, sample aliquots of 1 mL were taken (and immediately diluted) after incubation periods of: T=5 min, T=15 min, T=60 min, T=180 min, T=360 min.
The samples collected during the different incubation assays of the eluate matrix “FVII Select” (that contain PG at 45%) are summarized in the Table V.
The samples, after titration, were stored at a temperature below −65° C. In addition, controls were generated with low, average and high viral load, by spiking of the matrix diluted in a non-cytotoxic and non-interfering concentration with the TGEV and BVDV viruses.
The incubation assays of the matrix containing 45% PG were considered successful if the following conditions were satisfied:
Titration of the Samples of Process.
The titration of the samples generated during the above-described assays was done on the same day.
Titration Protocol.
The titration of viruses of the samples shown in Table III was performed according to the study L-50 for TGEV and L-319 for BVDV.
The titration was done in three steps: seeding of the 96-wells plates, infection of said plates in standard titration or LVP (Large Volume Plating) and determination of the titer.
Seeding conditions of the 96-wells plates for the titration of each of the viruses are described in Table VI.
For each virus:
The titrations were performed immediately after the treatment assays; without freezing the samples.
Standard Titration.
The culture supernatant was removed and replaced by 20 μL of the sample to be titrated.
After a one-hour incubation at 37° C., 130 μL of culture medium was added to each well. Viral propagation resulted in a total or partial destruction of the cell coat.
For each dilution, 12 infection replicates were performed in order to permit a statistic analysis according to the Kärber and/or Spearman-Kärber methods, (See e.g., Chapter 5 of “Virology Labfax”, Bios Publishers (plus Academic Press (US), or Blackwell non-US, 1993; Karber, G. (1931). Arch. J. Exper. Path. u. pharmakol., 162, 480; Spearman (1908). Brit. J. Psychol., 2:227-242).
LVP Titration.
The viral titration method “Large Volume Plating” in “n” replicates allows for an increase in tested sample volume and thus an increase in the detection limit. The protocol is identical to the standard titration, except that the analysis was done using only one sample dilution, placed in all the wells of one or more 96-wells plate(s). The statistic analysis was done according to the method of Spearman-Kärber.
Controls.
In parallel with the sample titration, the following controls were performed:
Validity of a Titration Assay.
A titration assay was considered valid if:
Calculation of Titers, Charges and Reduction Factor.
After an incubation period of six days (for each of the viruses), for each well of each of the dilutions, the number of cells that had a total or partial destruction of the cell coat were quantified (with a microscope at size ×40 and/or ×100). The virus titer in each well was determined according to the Kärber formula, expressed in TCID50/mL (in log10).
The titer of viral suspension was calculated according to the Karber method. The titration of a virus was given with an uncertainty of ±0.5 log10 TCID50/mL and was calculated with the formula:
wherein: pi is the rate of positive wells at dilution i.
However, if the virus was only observed at the first tested dilution of the sample, and its infection rate was lower than 100%, the logarithmic concentration of virus in TCID50/mL was calculated according to the formula of the method of Spearman Kärber:
wherein
With the titers and viral loads expressed here in decimal value, the total viral load in a sample was calculated with the titer and the sample volume according to this formula:
Total viral load=titer×sample volume(mL).
The reduction factor (RF) was calculated compared to the viral load in the <<T0>> sample.
RF=(total viral load in “T0”)/(total viral load in sample taken at a later time).
Results
TGEV Study on the Affinity Chromatography Eluate (in Presence of 45% PG).
The results are described in Table VIII and illustrated in
BVDV Study on the Affinity Chromatography Eluate (in Presence of 45% PG).
The results are described in Table IX and illustrated in
X-MuLV and PRV Studies on the Affinity Chromatography Eluate (in Presence of 45% PG).
A similar study was done on a affinity chromatography eluted with 45% PG using the X-MuIV and PRV viruses and including the determination of standard deviations.
Results are described in Tables X and XI.
The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.
This application is a national stage filing under 35 U.S.C. § 371 of international application PCT/IB2011/003271, filed Dec. 23, 2011, which claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application Ser. No. 61/428,416, filed Dec. 30, 2010, the disclosure of which is incorporated by reference herein in its entirety.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/IB2011/003271 | 12/23/2011 | WO | 7/23/2013 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2012/090067 | 7/5/2012 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3910999 | Moyer | Oct 1975 | A |
| 4020183 | Asculai et al. | Apr 1977 | A |
| 4299828 | Wang et al. | Nov 1981 | A |
| 4420398 | Castino | Dec 1983 | A |
| 4612169 | Iwasaki et al. | Sep 1986 | A |
| 4764369 | Neurath et al. | Aug 1988 | A |
| 5145663 | Simmons | Sep 1992 | A |
| 5356651 | Degen et al. | Oct 1994 | A |
| 5576040 | Moller et al. | Nov 1996 | A |
| 5648253 | Wei | Jul 1997 | A |
| 5756687 | Denman et al. | May 1998 | A |
| 5827690 | Meade et al. | Oct 1998 | A |
| 5843705 | DiTullio et al. | Dec 1998 | A |
| 5849992 | Meade et al. | Dec 1998 | A |
| 6210736 | Echelard et al. | Apr 2001 | B1 |
| 6268487 | Kutzko et al. | Jul 2001 | B1 |
| 6441145 | DiTullio et al. | Aug 2002 | B1 |
| 6448469 | Smith | Sep 2002 | B1 |
| 6472584 | Smith | Oct 2002 | B1 |
| 6528699 | Meade et al. | Mar 2003 | B1 |
| 6545198 | Echelard et al. | Apr 2003 | B1 |
| 6548653 | Young et al. | Apr 2003 | B1 |
| 6580017 | Echelard et al. | Jun 2003 | B1 |
| 6593463 | Chen et al. | Jul 2003 | B1 |
| 6727405 | Gordon et al. | Apr 2004 | B1 |
| 6743966 | Smith | Jun 2004 | B2 |
| 7019193 | Ditullio et al. | Mar 2006 | B2 |
| 7026154 | Gaillac et al. | Apr 2006 | B1 |
| 7045676 | Gordon et al. | May 2006 | B1 |
| 7087719 | Visuri et al. | Aug 2006 | B2 |
| 7101971 | Meade et al. | Sep 2006 | B2 |
| 7354594 | Chen et al. | Apr 2008 | B2 |
| 7501553 | Chen et al. | Mar 2009 | B2 |
| 7531632 | Perreault | May 2009 | B2 |
| 7550263 | Meade et al. | Jun 2009 | B2 |
| 7632980 | Chen et al. | Dec 2009 | B1 |
| 7651686 | Chen et al. | Jan 2010 | B2 |
| 7928064 | DiTullio et al. | Apr 2011 | B2 |
| 7939317 | Gordon et al. | May 2011 | B1 |
| 8173860 | Meade et al. | May 2012 | B2 |
| 8252227 | Bardat | Aug 2012 | B2 |
| 9029316 | Bardat et al. | May 2015 | B2 |
| 9102762 | Christensen et al. | Aug 2015 | B2 |
| 9358275 | Bardat et al. | Jun 2016 | B2 |
| 9511087 | Frieling et al. | Dec 2016 | B2 |
| 10034921 | Chen et al. | Jul 2018 | B2 |
| 10174110 | Meade et al. | Jan 2019 | B2 |
| 10611826 | Paolantonacci et al. | Apr 2020 | B2 |
| 20020131957 | Gavin et al. | Sep 2002 | A1 |
| 20020144299 | Chen et al. | Oct 2002 | A1 |
| 20020155998 | Young et al. | Oct 2002 | A1 |
| 20030005468 | Meade et al. | Jan 2003 | A1 |
| 20030033618 | Smith | Feb 2003 | A1 |
| 20030036637 | Fulton | Feb 2003 | A1 |
| 20030046716 | Echelard et al. | Mar 2003 | A1 |
| 20030096974 | Ditullio et al. | May 2003 | A1 |
| 20030177513 | Echelard et al. | Sep 2003 | A1 |
| 20030204860 | Melican et al. | Oct 2003 | A1 |
| 20030213003 | Meade et al. | Nov 2003 | A1 |
| 20040006776 | Meade et al. | Jan 2004 | A1 |
| 20040025193 | Echelard et al. | Feb 2004 | A1 |
| 20040092719 | Birck-Wilson et al. | May 2004 | A1 |
| 20040097710 | Visuri et al. | May 2004 | A1 |
| 20040098755 | Mulroy et al. | May 2004 | A1 |
| 20040102380 | Fulton et al. | May 2004 | A1 |
| 20040109847 | Chen et al. | Jun 2004 | A1 |
| 20040117863 | Edge et al. | Jun 2004 | A1 |
| 20040121303 | Gavin et al. | Jun 2004 | A1 |
| 20040133931 | Gavin et al. | Jul 2004 | A1 |
| 20040143857 | Young et al. | Jul 2004 | A1 |
| 20040148648 | Behboodi et al. | Jul 2004 | A1 |
| 20040167320 | Couto et al. | Aug 2004 | A1 |
| 20040192595 | Murakami et al. | Sep 2004 | A1 |
| 20040205832 | Meade et al. | Oct 2004 | A1 |
| 20040226052 | Meade et al. | Nov 2004 | A1 |
| 20040226053 | Meade et al. | Nov 2004 | A1 |
| 20050006307 | Jones et al. | Jan 2005 | A1 |
| 20050013811 | Chen et al. | Jan 2005 | A1 |
| 20050029195 | Gibson et al. | Feb 2005 | A1 |
| 20050060766 | Chen | Mar 2005 | A1 |
| 20050071890 | Chen et al. | Mar 2005 | A1 |
| 20050097625 | Meade et al. | May 2005 | A1 |
| 20050158832 | Young et al. | Jul 2005 | A1 |
| 20050160483 | Meade et al. | Jul 2005 | A1 |
| 20050169908 | Murakami et al. | Aug 2005 | A1 |
| 20050177882 | Gavin et al. | Aug 2005 | A1 |
| 20050181482 | Meade et al. | Aug 2005 | A1 |
| 20050186608 | Olsen | Aug 2005 | A1 |
| 20050192226 | Enkhbaatar et al. | Sep 2005 | A1 |
| 20050193431 | Echelard et al. | Sep 2005 | A1 |
| 20050197496 | Perreault | Sep 2005 | A1 |
| 20050208000 | Bernstein et al. | Sep 2005 | A1 |
| 20050235371 | Chen et al. | Oct 2005 | A1 |
| 20050245444 | Echelard et al. | Nov 2005 | A1 |
| 20050260672 | Couto et al. | Nov 2005 | A1 |
| 20060026695 | Edge et al. | Feb 2006 | A1 |
| 20060105347 | Meade et al. | May 2006 | A1 |
| 20060121004 | Echelard et al. | Jun 2006 | A1 |
| 20060123500 | Echelard et al. | Jun 2006 | A1 |
| 20060130159 | Masiello et al. | Jun 2006 | A1 |
| 20060168671 | Gavin et al. | Jul 2006 | A1 |
| 20060174359 | Melican et al. | Aug 2006 | A1 |
| 20060178309 | Visuri et al. | Aug 2006 | A1 |
| 20060179493 | Meade et al. | Aug 2006 | A1 |
| 20060179500 | Meade et al. | Aug 2006 | A1 |
| 20060182744 | Strome et al. | Aug 2006 | A1 |
| 20060191025 | Echelard et al. | Aug 2006 | A1 |
| 20060191029 | Gavin et al. | Aug 2006 | A1 |
| 20060286548 | Liposky et al. | Dec 2006 | A1 |
| 20070037192 | Ziomek et al. | Feb 2007 | A1 |
| 20070192878 | Perreault | Aug 2007 | A1 |
| 20080004212 | Echelard et al. | Jan 2008 | A1 |
| 20080019905 | Strome et al. | Jan 2008 | A9 |
| 20080063780 | Meade et al. | Mar 2008 | A1 |
| 20080118501 | Schindler et al. | May 2008 | A1 |
| 20080176786 | Ditullio et al. | Jul 2008 | A1 |
| 20090068193 | Chen et al. | Mar 2009 | A1 |
| 20090246194 | Meade et al. | Oct 2009 | A1 |
| 20090311239 | Chtourou et al. | Dec 2009 | A1 |
| 20100021612 | Meade et al. | Jan 2010 | A1 |
| 20100056757 | Perreault | Mar 2010 | A1 |
| 20110070167 | Enkhbaatar et al. | Mar 2011 | A1 |
| 20110082083 | Magneson et al. | Apr 2011 | A1 |
| 20110229460 | Meade | Sep 2011 | A1 |
| 20120058047 | Strome et al. | Mar 2012 | A9 |
| 20130149301 | Meade | Jun 2013 | A1 |
| 20130324619 | Chtourou | Dec 2013 | A1 |
| 20140046033 | Schindler et al. | Feb 2014 | A1 |
| 20140194360 | Frieling et al. | Jul 2014 | A1 |
| 20140206617 | Frieling et al. | Jul 2014 | A1 |
| 20140228301 | Meade et al. | Aug 2014 | A1 |
| 20140242182 | Evans et al. | Aug 2014 | A1 |
| 20140296490 | Faid et al. | Oct 2014 | A1 |
| 20150152162 | Boulange et al. | Jun 2015 | A1 |
| 20150175983 | Bataille et al. | Jun 2015 | A1 |
| 20150368334 | Meade et al. | Dec 2015 | A1 |
| 20150368357 | Meade et al. | Dec 2015 | A1 |
| 20150374801 | Chen et al. | Dec 2015 | A1 |
| 20160002330 | Meade | Jan 2016 | A1 |
| 20160039913 | Meade et al. | Feb 2016 | A1 |
| 20160089422 | Chtourou et al. | Mar 2016 | A1 |
| 20160129115 | Magneson et al. | May 2016 | A1 |
| 20160158676 | Hawkins et al. | Jun 2016 | A1 |
| 20160168229 | Paolantonacci et al. | Jun 2016 | A1 |
| 20160326547 | Meade et al. | Nov 2016 | A1 |
| 20170121402 | Chtourou | May 2017 | A1 |
| 20170129966 | Masiello | May 2017 | A1 |
| 20170190753 | Abache | Jul 2017 | A1 |
| 20180139938 | Chen | May 2018 | A1 |
| 20180169297 | Chtourou et al. | Jun 2018 | A1 |
| 20180355034 | Mondon et al. | Dec 2018 | A1 |
| 20190254276 | Chtourou | Aug 2019 | A1 |
| 20190309057 | Meade et al. | Oct 2019 | A1 |
| 20190309058 | Meade et al. | Oct 2019 | A1 |
| 20200255518 | Schindler et al. | Aug 2020 | A1 |
| 20200331994 | Chtourou et al. | Oct 2020 | A1 |
| 20210275668 | Plantier et al. | Sep 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 962514 | Feb 1975 | CA |
| 101065118 | Oct 2007 | CN |
| 1829736 | Sep 2009 | CN |
| 0638242 | Jan 1995 | EP |
| 0 819 968 | Jan 1998 | EP |
| 0804074 | Jan 2005 | EP |
| 2350271 | Jan 2016 | EP |
| S46-6912 | Mar 1971 | JP |
| S55-164627 | Dec 1980 | JP |
| S59-175879 | Oct 1984 | JP |
| H04-503067 | Jun 1992 | JP |
| H07-126109 | May 1995 | JP |
| H09-206362 | Aug 1997 | JP |
| H10-507367 | Jul 1998 | JP |
| 2008-531700 | Aug 2008 | JP |
| 2012-509081 | Apr 2012 | JP |
| WO 9008559 | Aug 1990 | WO |
| WO 9429334 | Dec 1994 | WO |
| WO 1995002393 | Jan 1995 | WO |
| WO 9502393 | Jan 1995 | WO |
| WO 9614737 | May 1996 | WO |
| WO 9964462 | Dec 1999 | WO |
| WO 1999064441 | Dec 1999 | WO |
| WO 2002058747 | Aug 2002 | WO |
| WO 2004011023 | Feb 2004 | WO |
| WO 2004092360 | Oct 2004 | WO |
| WO 2006093924 | Sep 2006 | WO |
| WO 2009110940 | Sep 2009 | WO |
| WO 2010009388 | Jan 2010 | WO |
| WO 2010059232 | May 2010 | WO |
| WO 2013066251 | May 2013 | WO |
| Entry |
|---|
| Dunham, W. B., and W. J. MacNeal. “Inactivation of Influenza Virus by Mild Antiseptics.” Journal of Immunology 49.2 (1944): 123-8. |
| Scientific Report of EFSA, Available data on notified biocides efficacy under field conditions (compared to sodium hydroxide and sodium carbonate), European Food Safety Authority, European Food Safety Authority (EFSA), EFSA Journal 2009; 7 (10):259 (Year: 2009). |
| Jack A. Ragheb, The Amphotropic and Ecotropic Murine Leukemia Virus Envelope . . . , Journal of Virology, Nov. 1995, p. 7205-7215 (Year: 1995). |
| S. Davison, C. E. Benson, A. F. Ziegler, and R. J. Eckroade, Evaluation of Disinfectants with the Addition of Antifreezing Compounds Against Nonpathogenic H7N2 Avian Influenza Virus, Avian Diseases 43:533-537, 1999 (Year: 1999). |
| The pressure washing forum (dated 2009, downloaded Aug. 22, 2019) (Year: 2009). |
| O. H. Robertson, M.D.,The Bactericidal Action of Propylene Glycol Vapor on Microorganisms Suspended in Air. I, J Exp Med. Jun. 1, 1942; 75(6): 593-610 (Year: 1942). |
| I. Olitzky, Antimicrobial Properties of a Propylene Glycol Based Topical Therapeutic Agent, Journal of Pharmaceutical Sciences, vol. 54, No. 5, May 1965, 787-788 (Year: 1965). |
| Wikipedia page for Protein purification (Year: 2021). |
| PCT/IB2011/003271, dated May 10, 2012, International Search Report and Written Opinion. |
| PCT/IB2011/003271, dated Jul. 11, 2013, International Preliminary Report on Patentability. |
| Burnouf et al., Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia. Jan. 2003;9(1):24-37. |
| Hill et al., Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia. Jan. 2003;9(1):1-23. |
| Mollerup et al., The Use of RP-HPLC for measuring activation and cleavage of rFVIIa during purification. Biotechnol Bioeng. Dec. 5, 1995;48(5):501-5. |
| Pedersen et al., Auto activation of human recombinant coagulation factor VII. Biochemistry. Nov. 28, 1989;28(24):9331-6. |
| Tomokiyo et al., Large-scale production and properties of human plasma-derived activated Factor VII concentrate. Vox Sang. Jan. 2003;84(1):54-64. |
| Aranha-Creado et al., Cumulative Viral Titer Reduction Demonstrated by Sequential Challenge of a Tangential Flow Membrane Filtration System and a Direct Flow Pleated Filter Cartridge. PDA J Pharm Sci Technol. Sep. 1997;51(5):208-212. |
| Bryant et al., Pathogen Inactivation: The Definitive Safeguard for the Blood Supply. Arch Pathol Lab Med. May 2007;131(5):719-33. |
| Chang, Transfusion therapy in critically ill children. Pediatr Neonatol. Apr. 2008;49(2):5-12. doi:10.1016/S1875-9572(08)60004-2. |
| Cohn et al., Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids 1a,b,c,d J Am Chem Soc. Mar. 1946;68:459-75. |
| Oncley et al., The Separation of the Antibodies, Isoagglutinins, Prothrombin, Plasminogen and β1-Lipoprotein into Subfractions of Human Plasma. J Am Chem Soc. Feb. 1949;71(2):541-50. |
| [No Author Listed] The pressure washing forum. Apr. 9, 2009. Retrieved from the internet on Aug. 22, 2019. 1 page. |
| Davison et al., Evaluation of disinfectants with the addition of antifreezing compounds against nonpathogenic H7N2 avian influenza virus. Avian Dis. Jul.-Sep. 1999;43(3):533-7. |
| Lorenz et al., Use-Dilution Test and Newcastle Disease Virus. Appl Microbiol. Jan. 1964;12:24-6. |
| Robertson et al., The bactericidal action of propylene glycol vapor on microorganisms suspended in air. I. J Exp Med. Jun. 1, 1942;75(6):593-610. |
| Extended European Search Report for Application No. EP 20173998.4 dated May 14, 2021. |
| Anthony et al., A strategy to estimate unknown viral diversity in mammals. mBio. Sep. 3, 2013;4(5):e00598-13. doi: 10.1128/mBio.00598-13. |
| EP 20173998.4, dated May 14, 2021, Extended European Search Report. |
| Number | Date | Country | |
|---|---|---|---|
| 20130324619 A1 | Dec 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61428416 | Dec 2010 | US |
